Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04016935 · ClinicalTrials.gov registry record
EndoPredict® Extended Endocrine Trial (EXET)
A clinical trial, sponsored by Myriad Genetic Laboratories.
- Terminated
- Registry status
- 855
- Enrollment target
NCT04016935: Clinical Trial study, sponsored by Myriad Genetic Laboratories.
NCT04016935 is a clinical trial that was terminated before completion, run by Myriad Genetic Laboratories. The registered enrollment target is 855 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04016935 was terminated before completion, sponsored by Myriad Genetic Laboratories.
- TERMINATED
- Registry status
- 855 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the impact of using EndoPredict® clinically to inform treatment decisions for extended endocrine therapy, and the subsequent impact on patient outcomes.
Primary Outcome
The primary objective of this study is to evaluate distant recurrence-free survival (DRFS) between years 5 and 10 post-diagnosis of women with ER+, HER2- breast cancer who are classified as low risk according to their EPclin score and who did not receive extended endocrine therapy
Interventions
- OTHER Observational
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 855 participants |
| Start Date | 2019-07-02 |
| Est. Completion | 2022-03-31 |
Why NCT04016935 stopped before completion
NCT04016935 is an observational study that tracks outcomes without assigning an intervention. The registered 855 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Observational is the first listed.
NCT04016935 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04016935 about?
NCT04016935 is a clinical study titled "EndoPredict® Extended Endocrine Trial (EXET)". The purpose of this study is to evaluate the impact of using EndoPredict® clinically to inform treatment decisions for extended endocrine therapy, and the subsequent impact on patient outcomes.
What is the current status of trial NCT04016935?
This trial is currently terminated. The enrollment target is 855 participants. The study started on 2019-07-02. Estimated completion is 2022-03-31.
What interventions are being tested in trial NCT04016935?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT04016935?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05108896 · 855 participants · NA
Aspiration in Acute Respiratory Failure Survivors 2
- NCT06231485 · 856 participants · NA
Socialization To Enrich Participation & Support Sexuality for Young People With I/DD
- NCT07005102 · 854 participants · Phase 2
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- NCT07290491 · 854 participants · Phase 3
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI